Search
Search
We can't wait to see you in person at the 2021 Society for Immunotherapy of Cancer (SITC) congress taking place November 12-14 in Washington, DC.
Stop by booth #802 to speak with our staff about the latest innovations in next-generation sequencing (NGS) and other solutions to take your immuno-oncology research to the next level.
If you’re unable to join us in person, you can still request an interactive, virtual demonstration of some of the products that will be showcased in our booth.
The first turnkey next-generation sequencing (NGS) solution that automates the specimen-to-report workflow and delivers results in as little as single day with just two user touchpoints. This highly flexible system lets you process samples—even just one—cost-effectively as they come in. And its simplicity and practicality make it easy for your clinical research or testing lab to bring NGS in-house, regardless of your team’s current level of NGS expertise.
Confidently confirm your cell profiles with a new flow cytometer that delivers flow cytometry and imaging data simultaneously. Now, you can acquire dual data quickly and easily. The new Invitrogen Attune CytPix Flow Cytometer delivers both brightfield images and flow cytometry data sets simultaneously, so you can confirm cellular characteristics and sample quality confidently, without changing your protocols.
The Luminex xMAP INTELLIFLEX DR-SE System is the only compact, flow-based, multiplex platform that combines the proven performance of xMAP technology with modern features to enhance performance, empower assay development innovation, and simplify your user experience. No other multiplex platform combines low- and high-plex capabilities, quick time to reliable results, and the ability to simultaneously acquire data for two parameters per analyte simultaneously.
The Ion Torrent Oncomine BCR IGH LR Assay is a robust, targeted next-generation sequencing (NGS) assay designed for use in research applications in hematology-oncology, immuno-oncology, infectious disease, and basic immunology. Unlike other technologies, the Oncomine BCR IGH-LR Assay offers more than 400 base amplicons of library sequencing through long-read sequencing chemistry, enabling comprehensive coverage of the B-cell receptor (BCR) immunoglobin heavy (IGH) chain. The assay kit includes a single pool of multiplex PCR primers, cDNA synthesis kit, and Ion AmpliSeq library reagents.
The Oncomine Immune Response Research Assay is a targeted gene expression assay designed for the Ion NGS platform. This pan-cancer gene expression assay is designed to interrogate the tumor microenvironment to enable mechanistic studies and identification of potentially predictive biomarkers for immunotherapy in retrospective or prospective clinical trial research cohorts. The assay is optimized to measure the expression of genes involved in tumor-immune interactions, including the low-expressing genes involved in inflammatory signaling.
Investigate the immune repertoire by interrogating all regions of the TCR beta chain: CDR1, CDR2, and CDR3, with one assay. Analyzing the immune repertoire to capture the diversity of T cell receptor (TCR) rearrangements can help you make significant progress in immuno-oncology research. The Oncomine TCR Beta-LR Assay, provides researchers with a rapid, long-read NGS tool for studying the complexity of cellular immunology.
This product is available in different configurations, ranging from 48 up to 384 samples per kit to accommodate your Microbiome research needs. The product bundles provide reagents and materials for a cost-effective and comprehensive, targeted NGS workflow for highly sensitive, specific, and robust characterization of human gut microbiome from stool samples, with a full analysis solution providing optimized informatics and visualization.
We can't wait to see you in person at the 2021 Society for Immunotherapy of Cancer (SITC) congress taking place November 12-14 in Washington, DC.
Stop by booth #802 to speak with our staff about the latest innovations in next-generation sequencing (NGS) and other solutions to take your immuno-oncology research to the next level.
If you’re unable to join us in person, you can still request an interactive, virtual demonstration of some of the products that will be showcased in our booth.
The first turnkey next-generation sequencing (NGS) solution that automates the specimen-to-report workflow and delivers results in as little as single day with just two user touchpoints. This highly flexible system lets you process samples—even just one—cost-effectively as they come in. And its simplicity and practicality make it easy for your clinical research or testing lab to bring NGS in-house, regardless of your team’s current level of NGS expertise.
Confidently confirm your cell profiles with a new flow cytometer that delivers flow cytometry and imaging data simultaneously. Now, you can acquire dual data quickly and easily. The new Invitrogen Attune CytPix Flow Cytometer delivers both brightfield images and flow cytometry data sets simultaneously, so you can confirm cellular characteristics and sample quality confidently, without changing your protocols.
The Luminex xMAP INTELLIFLEX DR-SE System is the only compact, flow-based, multiplex platform that combines the proven performance of xMAP technology with modern features to enhance performance, empower assay development innovation, and simplify your user experience. No other multiplex platform combines low- and high-plex capabilities, quick time to reliable results, and the ability to simultaneously acquire data for two parameters per analyte simultaneously.
The Ion Torrent Oncomine BCR IGH LR Assay is a robust, targeted next-generation sequencing (NGS) assay designed for use in research applications in hematology-oncology, immuno-oncology, infectious disease, and basic immunology. Unlike other technologies, the Oncomine BCR IGH-LR Assay offers more than 400 base amplicons of library sequencing through long-read sequencing chemistry, enabling comprehensive coverage of the B-cell receptor (BCR) immunoglobin heavy (IGH) chain. The assay kit includes a single pool of multiplex PCR primers, cDNA synthesis kit, and Ion AmpliSeq library reagents.
The Oncomine Immune Response Research Assay is a targeted gene expression assay designed for the Ion NGS platform. This pan-cancer gene expression assay is designed to interrogate the tumor microenvironment to enable mechanistic studies and identification of potentially predictive biomarkers for immunotherapy in retrospective or prospective clinical trial research cohorts. The assay is optimized to measure the expression of genes involved in tumor-immune interactions, including the low-expressing genes involved in inflammatory signaling.
Investigate the immune repertoire by interrogating all regions of the TCR beta chain: CDR1, CDR2, and CDR3, with one assay. Analyzing the immune repertoire to capture the diversity of T cell receptor (TCR) rearrangements can help you make significant progress in immuno-oncology research. The Oncomine TCR Beta-LR Assay, provides researchers with a rapid, long-read NGS tool for studying the complexity of cellular immunology.
This product is available in different configurations, ranging from 48 up to 384 samples per kit to accommodate your Microbiome research needs. The product bundles provide reagents and materials for a cost-effective and comprehensive, targeted NGS workflow for highly sensitive, specific, and robust characterization of human gut microbiome from stool samples, with a full analysis solution providing optimized informatics and visualization.
Perform a virtual NGS run on the Ion Torrest Genexus Integrated Sequencer or visualize how the instrument will fit in your own lab.
The Immuno-Oncology Product Resource Guide is an introduction to immuno-oncology research, covering key approaches such as CAR T-cell therapy research and solutions for each application area.
For Research Use Only. Not for use in diagnostic procedures.











